Correlation Between Emergent Biosolutions and Supernus Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Emergent Biosolutions and Supernus Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Emergent Biosolutions and Supernus Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Emergent Biosolutions and Supernus Pharmaceuticals, you can compare the effects of market volatilities on Emergent Biosolutions and Supernus Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Emergent Biosolutions with a short position of Supernus Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Emergent Biosolutions and Supernus Pharmaceuticals.

Diversification Opportunities for Emergent Biosolutions and Supernus Pharmaceuticals

0.69

Correlation Coefficient

Emergent Biosolutions  Supernus Pharmaceuticals

Poor diversification

The 3 months correlation between Emergent and Supernus is 0.69. Overlapping area represents the amount of risk that can be diversified away by holding Emergent Biosolutions and Supernus Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Supernus Pharmaceuticals and Emergent Biosolutions is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Emergent Biosolutions are associated (or correlated) with Supernus Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Supernus Pharmaceuticals has no effect on the direction of Emergent Biosolutions i.e., Emergent Biosolutions and Supernus Pharmaceuticals go up and down completely randomly.

Pair Corralation between Emergent Biosolutions and Supernus Pharmaceuticals

Considering the 90-day investment horizon Emergent Biosolutions is expected to generate 4.57 times more return on investment than Supernus Pharmaceuticals. However, Emergent Biosolutions is 4.57 times more volatile than Supernus Pharmaceuticals. It trades about 0.1 of its potential returns per unit of risk. Supernus Pharmaceuticals is currently generating about 0.06 per unit of risk. If you would invest  234.00  in Emergent Biosolutions on September 13, 2024 and sell it today you would earn a total of  623.00  from holding Emergent Biosolutions or generate 266.24% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Emergent Biosolutions  vs.  Supernus Pharmaceuticals

Emergent Biosolutions

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Emergent Biosolutions are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain fundamental drivers, Emergent Biosolutions unveiled solid returns over the last few months and may actually be approaching a breakup point.

Supernus Pharmaceuticals

Risk-Adjusted Performance

12 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Supernus Pharmaceuticals are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain basic indicators, Supernus Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Emergent Biosolutions and Supernus Pharmaceuticals

The main advantage of trading using opposite Emergent Biosolutions and Supernus Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Emergent Biosolutions position performs unexpectedly, Supernus Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Supernus Pharmaceuticals will offset losses from the drop in Supernus Pharmaceuticals' long position.

The idea behind Emergent Biosolutions and Supernus Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.